Cargando…
Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients
AIM: To investigate the role of genetic variants of angiotensin converting enzyme (ACE) and angiotensinogen (AGT) genes in the antiproteinuric efficacy of ACE inhibitor therapy in diabetic nephropathy (DN) patients. METHODS: In the present study, 270 type 2 diabetes mellitus patients with nephropath...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348623/ https://www.ncbi.nlm.nih.gov/pubmed/28344754 http://dx.doi.org/10.4239/wjd.v8.i3.112 |
_version_ | 1782514270226874368 |
---|---|
author | Aggarwal, Neerja Kare, Pawan Kumar Varshney, Parul Kalra, Om Prakash Madhu, Sri Venkata Banerjee, Basu Dev Yadav, Anil Raizada, Alpana Tripathi, Ashok Kumar |
author_facet | Aggarwal, Neerja Kare, Pawan Kumar Varshney, Parul Kalra, Om Prakash Madhu, Sri Venkata Banerjee, Basu Dev Yadav, Anil Raizada, Alpana Tripathi, Ashok Kumar |
author_sort | Aggarwal, Neerja |
collection | PubMed |
description | AIM: To investigate the role of genetic variants of angiotensin converting enzyme (ACE) and angiotensinogen (AGT) genes in the antiproteinuric efficacy of ACE inhibitor therapy in diabetic nephropathy (DN) patients. METHODS: In the present study, 270 type 2 diabetes mellitus patients with nephropathy were enrolled and treated with ACE inhibitor (ramipril) and followed at 6 mo for renal function and albumin excretion by estimating serum creatinine, end stage renal disease, and albumin/creatinine ratio (ACR) in urine. Genotyping of ACE I/D and AGT M235T polymorphisms were performed by using primer specific polymerase chain reaction (PCR) and PCR-RFLP techniques, respectively. RESULTS: Forty-eight percent of DN patients (responders) benefited with respect to proteinuria from ACE inhibitor therapy at 6 mo follow-up. A significant reduction in ACR was observed after 6 mo treatment with ACE inhibitor irrespective of whether DN patients were micro-albuminuric (≥ 30 and < 300 mg/g creatinine) or macro-albuminuric (≥ 300 mg/g creatinine) at the time of enrollment. However, macro-albuminuric patients (55%) showed better response to therapy. A reduction in urinary ACR was found independent of genotypes of ACE I/D and AGT M235T polymorphisms although macro-albuminuric patients having TT genotype showed statistically insignificant increased response (72%). CONCLUSION: ACE inhibitor therapy reduced urinary ACR by ≥ 30% in 50% of DN patients and the response is independent of ACE I/D and AGT M235T polymorphisms. |
format | Online Article Text |
id | pubmed-5348623 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-53486232017-03-25 Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients Aggarwal, Neerja Kare, Pawan Kumar Varshney, Parul Kalra, Om Prakash Madhu, Sri Venkata Banerjee, Basu Dev Yadav, Anil Raizada, Alpana Tripathi, Ashok Kumar World J Diabetes Prospective Study AIM: To investigate the role of genetic variants of angiotensin converting enzyme (ACE) and angiotensinogen (AGT) genes in the antiproteinuric efficacy of ACE inhibitor therapy in diabetic nephropathy (DN) patients. METHODS: In the present study, 270 type 2 diabetes mellitus patients with nephropathy were enrolled and treated with ACE inhibitor (ramipril) and followed at 6 mo for renal function and albumin excretion by estimating serum creatinine, end stage renal disease, and albumin/creatinine ratio (ACR) in urine. Genotyping of ACE I/D and AGT M235T polymorphisms were performed by using primer specific polymerase chain reaction (PCR) and PCR-RFLP techniques, respectively. RESULTS: Forty-eight percent of DN patients (responders) benefited with respect to proteinuria from ACE inhibitor therapy at 6 mo follow-up. A significant reduction in ACR was observed after 6 mo treatment with ACE inhibitor irrespective of whether DN patients were micro-albuminuric (≥ 30 and < 300 mg/g creatinine) or macro-albuminuric (≥ 300 mg/g creatinine) at the time of enrollment. However, macro-albuminuric patients (55%) showed better response to therapy. A reduction in urinary ACR was found independent of genotypes of ACE I/D and AGT M235T polymorphisms although macro-albuminuric patients having TT genotype showed statistically insignificant increased response (72%). CONCLUSION: ACE inhibitor therapy reduced urinary ACR by ≥ 30% in 50% of DN patients and the response is independent of ACE I/D and AGT M235T polymorphisms. Baishideng Publishing Group Inc 2017-03-15 2017-03-15 /pmc/articles/PMC5348623/ /pubmed/28344754 http://dx.doi.org/10.4239/wjd.v8.i3.112 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Prospective Study Aggarwal, Neerja Kare, Pawan Kumar Varshney, Parul Kalra, Om Prakash Madhu, Sri Venkata Banerjee, Basu Dev Yadav, Anil Raizada, Alpana Tripathi, Ashok Kumar Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients |
title | Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients |
title_full | Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients |
title_fullStr | Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients |
title_full_unstemmed | Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients |
title_short | Role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients |
title_sort | role of angiotensin converting enzyme and angiotensinogen gene polymorphisms in angiotensin converting enzyme inhibitor-mediated antiproteinuric action in type 2 diabetic nephropathy patients |
topic | Prospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348623/ https://www.ncbi.nlm.nih.gov/pubmed/28344754 http://dx.doi.org/10.4239/wjd.v8.i3.112 |
work_keys_str_mv | AT aggarwalneerja roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT karepawankumar roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT varshneyparul roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT kalraomprakash roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT madhusrivenkata roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT banerjeebasudev roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT yadavanil roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT raizadaalpana roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients AT tripathiashokkumar roleofangiotensinconvertingenzymeandangiotensinogengenepolymorphismsinangiotensinconvertingenzymeinhibitormediatedantiproteinuricactionintype2diabeticnephropathypatients |